VEGF抵抗性AMDにおける進行抑制と網膜退縮

基本情報

NCT ID: NCT07005323
ステータス: 募集中
試験のフェーズ: 該当なし
試験タイプ: 介入
目標被験者数: 10
治験依頼者名: PharmaBio Corporation

概要

The goal of this clinical trial is to assess safety and efficacy in patients with Neovascular Age-related Macular Degeneration with no response to existing therapy. The main measures it aims to answer are: * Investigation of adverse events * Changes in clinical testing data * Changes in vital signs * Changes in intraocular pressure of the therapeutic eye * Changes in testing of anterior segment of the therapeutic eye Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy. Researchers will compare pre and post implantation of therapeutic eye to see if any safety issues recognized

対象疾患

Neovascular Age-related Macular Degeneration (AMD)

介入

Pars plana vitrectomy(PROCEDURE)

依頼者（Sponsor）

Pharmabio(INDUSTRY)

実施施設 (1)

山口大学医学部附属病院

Ube, Ymaguchi, Japan(RECRUITING)